TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10725769
Drug: No inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No inulin with 210 mg of calcium
Study: 1963648
Drug: IVGTT (0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVGTT (0.33 g/kg glucose solution)
Study: 1963648
Drug: IVGTT2 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVGTT2 (0.5 g/kg glucose solution)
Study: 1963648
Drug: IVGTT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVGTT + A (during aminophylline infusion)
Study: 26618456
Drug: HYC-24L (Juvéderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYC-24L (Juvéderm Ultra XC, 24 mg/mL hyaluronic acid with 0.3% lidocaine)
Study: 26618456
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, delayed treatment)
Study: 19773024
Drug: Dietetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietetic treatment + cognitive therapy
Study: 19773024
Drug: Dietetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietetic treatment + physical exercise
Study: 30156866
Drug: Continuous Subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Subcutaneous Insulin Infusion (CSII)
Study: 17357293
Drug: Continuous Intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Intravenous Insulin Infusion (IVII)
Study: 16845252
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg daily
Study: 1302160
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg + Lasix 20 mg daily
Study: 1302160
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with ramipril
Study: 3823619
Drug: Clofibate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate (500 mg t.i.d.)
Study: 31542339
Drug: Intravitreal 2
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal 2 mg aflibercept every 4 weeks (monthly)
Study: 31542339
Drug: Intravitreal 2
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal 2 mg aflibercept every 12 weeks (quarterly)
Study: 24716820
Drug: Automated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated insulin bolus advisor (EXP)
Study: 20236381
Drug: PITA injections
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PITA injections
Study: 20236381
Drug: No PITA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No PITA injections (Control)
Study: 12475841
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL (5 mg) terbutaline + 2 mL of 3% saline solution (group 2)
Study: 12475841
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL (5 mg) terbutaline + 2 mL of 0.9% saline solution (group 1)
Study: 9804214
Drug: Chronic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic low dose r-HFSH (group A)
Study: 7593449
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg, twice daily)
Study: 2180831
Drug: CHO‐5 (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐5 (5.0 g/100 ml carbohydrate solution)
Study: 2180831
Drug: CHO‐6 (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐6 (6.0 g/100 ml carbohydrate solution)
Study: 2180831
Drug: CHO‐7.5 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐7.5 (7.5 g/100 ml carbohydrate solution)
Study: 6990215
Drug: Labetalol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (300 mg twice a day)
Study: 9542480
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg twice a day)
Study: 6990215
Drug: Hydrallazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrallazine (50 mg twice a day)
Study: 7967758
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no exercise prescription)
Study: 11716166
Drug: nCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP treatment (n=33)
Study: 7926290
Drug: Insulin-resistant group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant group (SI: 0.31 +/‐ 0.06 x 10(‐4) min‐1.pmol/l‐1)
Study: 7926290
Drug: Insulin-sensitive group
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitive group (SI: 0.92 +/‐ 0.11 x 10(‐4) min‐1.pmol/l‐1)
Study: 2686428
Drug: Ciprofloxacin, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 200 mg every 12 hours
Study: 2686428
Drug: Ceftazidime, 2
Normalized name: CefTAZidime, 2 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime, 2 g every eight hours
Study: 21119031
Drug: HER2-targeted agents
Normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HER2-targeted agents (trastuzumab and lapatinib) with standard treatment (taxanes, anthracyclines, capecitabine, anastrozole, letrozole)
Study: 3103245
Drug: Cefotaxime (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (3 doses of 1 gram each at induction and 1 and 3 hours later)
Study: 3103245
Drug: Cefamandole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (3 doses of 1 gram each at induction and 1 and 3 hours later)
Study: 17471340
Drug: Mupirocin nasal
Normalized name: mupirocin Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin nasal ointment (twice daily for 5 days prior to surgery)
Study: 12945073
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no mupirocin treatment)
Study: 12542598
Drug: Terlipressin 1
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin 1 mg i.v. at 12‐h intervals (group A)
Study: 10711411
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (4 IU/m2 per day, subcutaneous injections, every evening for 6 months)
Study: 28960867
Drug: Digitalis therapy
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis therapy
Study: 11852171
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory agents
Study: 31170994
Drug: AITC cough
Normalized name: Pediaclear Cough
Approvals — FDA: no, EMA: no, PMDA: no
Description: AITC cough challenge (selective TRPA1 agonist)
Study: 31170994
Drug: Capsaicin cough
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cough challenge (selective TRPV1 agonist)
Study: 29106594
Drug: Estradiol therapy
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol therapy (n = 21)
Study: 27041733
Drug: Pasireotide administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide administration after pancreatic resection
Study: 22377745
Drug: Paroxetine 10
Normalized name: PARoxetine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 10 mg/d
Study: 22377745
Drug: Paroxetine 10
Normalized name: PARoxetine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 10 mg/d and 20 mg/d
Study: 19297314
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 on day 1
Study: 19297314
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 on day 5 with oblimersen 7 mg/kg/day continuous i.v. infusion on days 1-7
Study: 17697219
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 microg x ml(‐1) combined with prolonged injection (30 s) (Group IV)
Study: 17697219
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 microg x ml(‐1) (Group I)
Study: 17697219
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 microg x ml(‐1) (Group II)
Study: 17697219
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 microg x ml(‐1) (Group III)
Study: 9710871
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution (0.7 g/kg BW/h)
Study: 9710871
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution plus caffeine (5 mg/kg BW)
Study: 3056237
Drug: Ceftizoxime (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime (30 mg/kg)
Study: 3056237
Drug: Cefoxitin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (30 mg/kg)
Study: 4881068
Drug: Suramin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin 1.0 g, 0.5 g, and 0.25 g dosages
Study: 28301561
Drug: 90-minute hatha
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-minute hatha yoga practice groups twice weekly for 8 weeks
Study: 28301561
Drug: 90-minute attention
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-minute attention control education groups twice weekly for 8 weeks
Study: 24519034
Drug: ACE- group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE- group (standard ISSNHL treatment regimen only)
Study: 23754736
Drug: Sifalimumab administered
Normalized name: Sifalimumab
DrugBank: Sifalimumab (DB12773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sifalimumab administered every 14 days as a 30- to 60-minute intravenous infusion with escalating doses of 0.3, 1.0, 3.0, and 10 mg/kg.
Study: 23754736
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing of sifalimumab at 200, 600, and 1,200 mg monthly (with a loading dose at Day 14).
Study: 9414336
Drug: Alternative keyboard
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative keyboard designs (e.g. split keyboard, laterally inclined halves)
Study: 8466068
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of regular insulin (20 u) followed by a glucose infusion (500 ml 5% dextrose in water) over 15 min
Study: 8466068
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of regular insulin (20 u)
Study: 3082644
Drug: Fluvoxamine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine, 50 mg twice a day
Study: 3082644
Drug: Mianserin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin, 20 mg twice a day
Study: 31995130
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication alone
Study: 29617064
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication with CGT
Study: 26970401
Drug: Certified nurse‐midwife
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certified nurse‐midwife telephone‐administered interpersonal psychotherapy (CNM‐IPT) sessions (up to eight 50-minute sessions)
Study: 25424297
Drug: Fentanyl (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (25 µg) combined with hyperbaric bupivacaine 0.5% (10mg)
Study: 25424297
Drug: Sufentanil (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (5.0 µg) combined with hyperbaric bupivacaine 0.5% (10mg)
Study: 12951862
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg, twice-weekly subcutaneous injections for 4 months)
Study: 11121908
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg twice daily (EAC)
Study: 11121908
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily (OAC)
Study: 7645790
Drug: Midazolam (Versed),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (Versed), 0.4 mg/kg
Study: 7645790
Drug: Ketamine (Ketalar),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (Ketalar), 3 mg/kg
Study: 3099943
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 800 mg five times daily for seven days
Study: 31167867
Drug: Caseworker-delivered multicomponent
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caseworker-delivered multicomponent intervention (behavioural counselling, nicotine spray, referral to Quitline and primary care)
Study: 23327023
Drug: Gargling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gargling with ketamine 40 mg in 30 ml saline for 60 seconds (Group K)
Study: 23327023
Drug: 0.05% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% betamethasone gel applied over endotracheal tube (Group B)
Study: 20874515
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg of H1N1 hemagglutinin vaccine
Study: 15942235
Drug: Cloxacillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin (2 g/day)
Study: 15942235
Drug: Pristinamycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pristinamycin (2 g/day)
Study: 10472877
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin (4.5 mU/minute initially, increased by 4.5 mU/minute every 30 minutes) for induction
Study: 10472877
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin (1.5 mU/minute initially, increased by 1.5 mU/minute every 30 minutes) for induction
Study: 10472877
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin for augmentation
Study: 10472877
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin for augmentation
Study: 10472877
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin for induction in nulliparous women
Study: 10472877
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin for induction in nulliparous women
Study: 10472877
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin for induction in nulliparous women (cephalopelvic disproportion)
Study: 10472877
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin for induction in nulliparous women (cephalopelvic disproportion)
Study: 6627821
Drug: Caffeine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (50 to 800 mg)
Study: 6627821
Drug: d-Amphetamine sulfate
Normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine sulfate (25 mg)
Study: 24418365
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) for 18 months without bisphosphonates
Study: 24418365
Drug: Shorter androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter androgen deprivation therapy (ADT) course combined with bisphosphonates
Study: 20498212
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy
Study: 23078756
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who lost drug free remission
Study: 19324974
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg or 80 mg)
Study: 12853502
Drug: Inhaled triamcinolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled triamcinolone, 1,200 microg daily
Study: 8538705
Drug: Two-component acellular
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-component acellular DTP vaccine (2566 children)
Study: 8538705
Drug: Five-component acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-component acellular DTP vaccine (2587 children)
Study: 8538705
Drug: Whole-cell DTP
Normalized name: ActHIB with Whole-Cell DTP Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell DTP vaccine (2102 children)
Study: 8538705
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (DT vaccine, 2574 children)
Study: 2070378
Drug: NH4F treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NH4F treatment
Study: 2070378
Drug: NaF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF treatment
Study: 7055433
Drug: 12 hours
Normalized name: PATCH, TRANSDERMAL 12 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 hours of penicillin G potassium and doxycycline hyclate
Study: 7055433
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of penicillin G potassium and doxycycline hyclate
Study: 7055433
Drug: 12 hours
Normalized name: PATCH, TRANSDERMAL 12 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 hours and 5 days of antibiotics
Study: 31782032
Drug: Intermittent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent chemotherapy (two times four cycles)
Study: 31782032
Drug: Continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chemotherapy (eight subsequent cycles)
Study: 20843608
Drug: Trier Social
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trier Social Stress Test for Groups (TSST-G)
Study: 25985446
Drug: AI/2-CDA (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI/2-CDA (6 mg/m²/d, days 1, 3) in combination with cytarabine/idarubicin (AI=500 mg/m² cytarabine 5 days continuous infusion plus 7 mg/m²/d idarubicin, days 3 and 5)
Study: 25985446
Drug: AI (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI (500 mg/m² cytarabine 5 days continuous infusion plus 7 mg/m²/d idarubicin, days 3 and 5)
Study: 21735660
Drug: Integrated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated therapy of traditional Chinese and Western medicine
Study: 21735660
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (transurethral plasmakentic vaporization, anti-infection, rehydration, and supportive therapies)
Study: 19906345
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d memantine
Study: 10507241
Drug: Amoxapine formulation
Normalized name: Amoxapine
DrugBank: Amoxapine (DB00543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxapine formulation 1
Study: 10507241
Drug: Amoxapine formulation
Normalized name: Amoxapine
DrugBank: Amoxapine (DB00543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxapine formulation 2
Study: 1755739
Drug: PhXA34 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA34 10 micrograms once daily for 7 days
Study: 27106176
Drug: Lyophilisate formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilisate formulation
Study: 27106176
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation
Study: 23146788
Drug: Newly diagnosed
Normalized name: AUTOLOGOUS CD34+ CELLS ISOLATED FROM BONE MARROW OF NEWLY DIAGNOSED X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (X-SCID) PATIENTS, TRANSDUCED EX VIVO WITH A SELF-INACTIVATING LENTIVIRAL VECTOR, ENCODING CODON-OPTIMIZED HUMAN INTERLEUKIN-2 RECEPTOR SUBUNIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly diagnosed type 1 diabetes (DMT1) patients immediately after treatment of diabetic ketoacidosis (study I)
Study: 17918321
Drug: Standard cardiotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cardiotropic therapy (nitrates, beta-blockers, ACE inhibitors on demand, diuretics, antioxidants) and placebo
Study: 17918321
Drug: Standard cardiotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cardiotropic therapy plus impase (1 tablet every other day for 3 months)
Study: 12018633
Drug: Intact parathyroid
Normalized name: Intact parathyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact parathyroid hormone (PTH) levels
Study: 10050221
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 1.0 mg/h
Study: 2041927
Drug: Erythromycin tablets
Normalized name: Erythromycin Tablets
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin tablets (Abboticin 500 mg tablets)
Study: 2041927
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid cream (Fucidin cream)
Study: 26260018
Drug: CO2 fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 fractional laser treatment (3 sessions every 4-6 weeks)
Study: 21747289
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration (OR) with D2O labeled fluid
Study: 21747289
Drug: Oral combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combined with intravenous rehydration (IVO) with D2O labeled fluid
Study: 9758292
Drug: Trovafloxacin 100
Normalized name: trovafloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 100 or 200 mg
Study: 9758292
Drug: Comparator (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (500 or 1000 mg amoxicillin, or 625 mg amoxicillin/clavulanic acid)